Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial >

Jyoti Prakash, CFA | Healthcare | Comment | 19 hours ago

Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial >

Jyoti Prakash, CFA | Healthcare | Comment | 19 hours ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.04

— 0.00 (−2.63)

As at 21/02/2025

Market capitalisation: AUD120m

View equity

Update

Healthcare

13.02.25

Actinogen Medical — XanaMIA Phase IIb/III study marches on

edison tv

Healthcare

24.01.25

Actinogen Medical – executive interview

Update

Healthcare

15.10.24

NZD2.72

▾ −0.08 (−2.86)

As at 21/02/2025

Market capitalisation: NZD294m

View equity

Update

Healthcare

29.11.24

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

Flash note

Healthcare

04.11.24

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Flash note

Healthcare

30.09.24

GBP0.06

— 0.00 (0.00)

As at 21/02/2025

Market capitalisation: GBP4m

View equity

Update

Healthcare

14.10.24

Argent Biopharma — Valuation report

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

CHF44.85

▾ 0.75 (1.70)

As at 21/02/2025

Market capitalisation: CHF581m

View equity

Flash

Healthcare

19.02.25

Basilea Pharmaceutica — Another year, another market beat

Flash

Healthcare

06.02.25

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Flash note

Healthcare

17.12.24

USD3.65

▾ 0.08 (2.24)

As at 21/02/2025

Market capitalisation: USD130m

View equity

Non client QV

Healthcare

29.01.25

SEK1.52

▾ −0.04 (−2.56)

As at 21/02/2025

Market capitalisation: SEK389m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK5.01

▾ 0.01 (0.20)

As at 21/02/2025

Market capitalisation: SEK1,405m

View equity

Flash

Healthcare

13.02.25

Cereno Scientific — CS014 achieves another Phase I milestone

edison tv

Healthcare

28.11.24

Cereno Scientific – executive interview

Update

Healthcare

28.11.24

SEK0.63

▾ −0.07 (−10.00)

As at 21/02/2025

Market capitalisation: SEK50m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.16

▾ 0.27 (1.70)

As at 21/02/2025

Market capitalisation: GBP66m

View equity

Flash

Healthcare

13.02.25

Creo Medical — Consumables business divestment concludes

Flash note

Healthcare

19.09.24

Creo Medical — Consumables business divested in strategic move

Flash note

Healthcare

05.07.24

SEK2.50

▾ −0.05 (−1.96)

As at 21/02/2025

Market capitalisation: SEK90m

View equity

Herantis Pharma (HRTIS)

Latest price

EUR1.51

▾ 0.02 (1.00)

As at 21/02/2025

Market capitalisation: EUR60m

View equity

Non client QV

Healthcare

20.01.25

USD1.78

▾ −0.10 (−5.32)

As at 21/02/2025

Market capitalisation: USD52m

View equity

Flash

Healthcare

13.02.25

Immix Biopharma — NXC-201 receives FDA RMAT designation

Outlook

Healthcare

15.01.25

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Flash note

Healthcare

04.10.24

SEK14.40

▾ 0.30 (2.13)

As at 21/02/2025

Market capitalisation: SEK731m

View equity

Flash

Healthcare

20.02.25

IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans

Flash

Healthcare

18.02.25

IRLAB Therapeutics — Financing improves operational flexibility

Update

Healthcare

14.02.25

EUR1.73

▾ 0.03 (1.53)

As at 21/02/2025

Market capitalisation: EUR26m

View equity

edison tv

Healthcare

29.10.24

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

edison tv

Healthcare

30.09.24

SEK8.14

▾ 0.04 (0.49)

As at 21/02/2025

Market capitalisation: SEK408m

View equity

Flash

Healthcare

21.02.25

Mendus — CADENCE trial enrols first patient

Update

Healthcare

20.02.25

Mendus — Vididencel on track in AML going into 2025

Flash

Healthcare

13.02.25

CHF10.36

▾ −0.30 (−2.81)

As at 21/02/2025

Market capitalisation: CHF213m

View equity

Update

Healthcare

17.01.25

Newron Pharmaceuticals — Spotlight on evenamide following licensing deals

Flash note

Healthcare

17.12.24

Newron Pharmaceuticals — Evenamide licence agreement in Japan

Update

Healthcare

23.09.24

Newron Pharmaceuticals — Moving full steam towards pivotal studies

See more
content on

Newron Pharmaceuticals

Equities

Equities by Sector

Sectors

Thematics

Latest

MediaWatch – What now?

Climate: Creating multi-trillion investment opportunities

ConsumerWatch – Looking for a sign

Audiovisual

Latest

Uncovering Trusts – abrdn Asian Income Fund (AAIF) – Asia as a region overlooked by income seekers

BAT – FY24 results highlights

BAT – A Better Tomorrow

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.04

Actinogen Medical — XanaMIA Phase IIb/III study marches on

Actinogen Medical – executive interview

Actinogen Medical — A$11.1m capital raise completed

See morecontent on

AFT Pharmaceuticals (AFT)

NZD2.72

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

See morecontent on

Argent Biopharma (RGT)

GBP0.06

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF44.85

Basilea Pharmaceutica — Another year, another market beat

Basilea Pharmaceutica — Encouraging start to the year for Cresemba

Basilea Pharmaceutica — Partner in place for US commercialisation of Zevtera

See morecontent on

Biomea Fusion (BMEA)

USD3.65

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

Cantargia (CANTA)

SEK1.52

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK5.01

Cereno Scientific — CS014 achieves another Phase I milestone

Cereno Scientific – executive interview

Cereno Scientific — A productive period with plenty more to come

See morecontent on

Chosa (CHOSA)

SEK0.63

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.16

Creo Medical — Consumables business divestment concludes

Creo Medical — Consumables business divested in strategic move

Creo Medical — Intuitive deal expansion is a notable milestone

See morecontent on

Elicera Therapeutics (ELIC)

SEK2.50

Herantis Pharma (HRTIS)

EUR1.51

Herantis Pharma — Potential disease-modifier for PD

See morecontent on

Immix Biopharma (IMMX)

USD1.78

Immix Biopharma — NXC-201 receives FDA RMAT designation

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Immix Biopharma — US CAR-T trial progresses to dose expansion

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on